{"id":"ad5fgf-4","safety":{"commonSideEffects":[{"rate":null,"effect":"Chest pain or angina"},{"rate":null,"effect":"Myocarditis or pericarditis"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug uses a replication-deficient adenovirus serotype 5 (Ad5) as a vector to deliver the FGF-4 gene directly into ischemic myocardium or other tissues. FGF-4 is a potent angiogenic factor that stimulates the formation of new blood vessels, thereby improving perfusion and oxygen delivery to damaged or ischemic tissue. This approach aims to restore functional blood flow in patients with severe coronary artery disease or peripheral arterial disease who are not candidates for conventional revascularization.","oneSentence":"Ad5FGF-4 is a gene therapy that delivers fibroblast growth factor 4 (FGF-4) via an adenovirus vector to promote angiogenesis and improve blood flow in ischemic tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:40.004Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe coronary artery disease with refractory angina"},{"name":"Critical limb ischemia / peripheral arterial disease"}]},"trialDetails":[{"nctId":"NCT02928094","phase":"PHASE3","title":"Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia","status":"UNKNOWN","sponsor":"Angionetics Inc.","startDate":"2023-01-01","conditions":"Angina, Stable","enrollment":160},{"nctId":"NCT01550614","phase":"PHASE3","title":"Efficacy and Safety of Ad5FGF-4 for Myocardial Ischemia in Patients With Stable Angina Due to Coronary Artery Disease","status":"TERMINATED","sponsor":"Cardium Therapeutics","startDate":"2012-03","conditions":"Angina, Stable","enrollment":11},{"nctId":"NCT00438867","phase":"PHASE3","title":"Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization","status":"UNKNOWN","sponsor":"Cardium Therapeutics","startDate":"2007-05","conditions":"Angina Pectoris","enrollment":300},{"nctId":"NCT00346437","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Intracoronary Ad5FGF-4 in Patients With Stable Angina (AGENT-3)","status":"COMPLETED","sponsor":"Cardium Therapeutics","startDate":"2001-10","conditions":"Angina Pectoris","enrollment":416},{"nctId":"NCT00185263","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of Intracoronary Ad5FGF-4 in Patients With Stable Angina","status":"UNKNOWN","sponsor":"Cardium Therapeutics","startDate":"2002-03","conditions":"Stable Angina","enrollment":116}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Generx","alferminogene tadenovec"],"phase":"phase_3","status":"active","brandName":"Ad5FGF-4","genericName":"Ad5FGF-4","companyName":"Angionetics Inc.","companyId":"angionetics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"Ad5FGF-4 is a gene therapy that delivers fibroblast growth factor 4 (FGF-4) via an adenovirus vector to promote angiogenesis and improve blood flow in ischemic tissues. Used for Severe coronary artery disease with refractory angina, Critical limb ischemia / peripheral arterial disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}